Introduction The management of wide QRS tachyarrhythmia was documented by advanced cardiac life support (ACLS) guidelines. Delayed or converted the arrhythmia.

Slides:



Advertisements
Similar presentations
Brugada’s Syndrome and Sudden Cardiac Death
Advertisements

Other Cardiac Conditions and the ECG
ECG in Ventricular arrhythmias
Ventricular Tachycardia
Thursday 4/12/2014 Hassan Alahmadi Medical Resident ( R1)
Ventricular Arrhythmias
Dental patients at risk with the use of epinephrine HTN CVA ASCAD- MI Cardiac arrythmias hyperthyroid sickle-cell anemia cocaine abuse MAOI.
Cardiac Arrhythmias.
Cardiac Arrhythmia. Cardiac Arrhythmia Definition: The pumping action of the heart is coordinated by an electrical system within the heart tissue.
Atrial Flutter Chris Caulfield AM Report 2/19/10.
Heart Remember or cardiac memory.  Background Can heart remember?
Arrhythmias: The Good, the Bad and the Ugly
Drugs used to treat cardiac arrhythmias
Dr LA Hodsdon. Amiodarone Been first-line drug for the treatment of stable ventricular tachycardia (VT) in recent years. 1 Reason for preference:
Ventricular Tachyarrhythmias
Arrhytmia In Heart Failure
Ventricular Arrhythmias Terry White, RN, EMT-P. Analyze the Rhythm.
Arrhythmias Medical Student Teaching Tuesday 24 th January 2012 Dr Karen Jones, SpR Emergency Medicine.
Arrhythmia recognition and treatment
Anti-arrhythmic drugs
Clinical Use of Antiarrhythmic Agents
Cardiac Arrhythmias in Coronary Heart Disease SIGN 94.
ANTIARRHYTHMIC DRUGS Department of Pharmacology and Toxicology
© Assoc. Prof. Ivan Lambev
Copyright © The McGraw-Hill Companies, Inc. Permission required for reproduction or display. 1 CHAPTER 23 Antiarrhythmic Drugs.
Amiodarone Use in Cardiac Surgical Resuscitation
Atrial Fibrillation Andreas Stein Robert Smith, M.D. August 11, 2003.
Department faculty and hospital therapy of medical faculty and department internal diseases of medical prophylactic faculty. Cardiac arrhythmia Docent.
Ventriclar Tachycardia
EKG Interpretation: Arrhythmias Mustafa Salehmohamed, D.O. Assistant Clinical Instructor Department of Medicine N.Y. College of Osteopathic Medicine October.
Good Morning 20 August Anesthetic Considerations in Patients With Cardiac Arrhythmias 麻醉科 林子富.
Case presentation Torsade de Pointes. C15 Case Mr X presented to ED from Bosbokrandt (Nelspruit area) visiting in CPT. He is previously well 28yr old.
Long QT and TdP Morning Report Elias Hanna, LSU Cardiology.
BIMM118 Cardiac Arrhythmia Arrhythmias : Abnormal rhythms of the heart that cause the heart to pump less effectively Arrhythmia occurs: –when the heart’s.
EP Show – Aug 2003 ICDs – Secondary prevention The EP Show: Which ICD for which patient? Part 1: Secondary prevention Eric Prystowsky MD Director, Clinical.
CT-1 Mechanistic Evaluation of the Effects of Ranolazine on Ventricular Repolarization Luiz Belardinelli, MD VP, Drug Research and Pharmacological Sciences.
Device and Antiarrhythmic Drugs: Advantages and Pitfalls Teresa Menendez Hood, M.D.
23 Antiarrhythmic Drugs.
Applied Therapeutics Dr. Riyadh Mustafa Al-Salih
Acquired Long QT Syndrome by Antiarrhythmic Drugs Chen Liying MD – Cardiology Department An Zhen Hospital Beijing CHINA. NASPE-Heart Rhythm Association.
1 Case 9 Stable Tachycardias © 2001 American Heart Association.
Arrhythmia Arrhythmias are abnormal beats of the heart.
1 Risk/Benefit Assessment Jeremy N. Ruskin, M.D. Director, Cardiac Arrhythmia Services Massachusetts General Hospital.
Antiarrhythmic Drugs.
The Case for Rate Control: In the Management of Atrial Fibrillation Charles W. Clogston, M.D. Cardiologist CHI St. Vincent Heart Clinic Arkansas April.
Copyright © 2014 Wolters Kluwer Health | Lippincott Williams & Wilkins Chapter 33 Disorders of Cardiac Conduction and Rhythm.
IN THE NAME OFGODIN THE NAME OFGOD SVTS.SAYAH.  All cardiac tachyarrhythmias are produced by: 1/disorders of impulse initiation :automatic 2/abnormalities.
ECG in myocardial ischemia and other pathologic processes Prof. Hanáček
ARRHYTHMIAS Jamil Mayet. Arrhythmias - learning objectives –Mechanisms of action of antiarrhythmic drugs –Diagnosis To differentiate the different types.
Cardiovascular Cardiovascular pharmacology pharmacology.
Department of Pharmacy, Ditmanson Medical Foundation Chia-Yi Christian Hospital Suspect Moxifloxacin Induced Torsades de Pointes: A case report Ya-Wen.
Palpitations and Common Arrhythmias J. Philip Saul, M.D. West Virginia University Morgantown, WV.
Date of download: 6/17/2016 Copyright © The American College of Cardiology. All rights reserved. From: The Morphology of the QT Interval Predicts Torsade.
Cardiac Arrhythmias An Introduction: Dr.S.Nandakumar.
MGR review R4. 장 원 석. Long QT Syndrome (LQTS) QT interval = beginning of the QRS to the end of the T wave duration of activation and recovery of the ventricular.
Tachykardie / bradykardie
Cardiac Catheterization Complication
RHYTHM ANALYSIS DAN MUSE, MD.
ECG Advanced Basics for Interns - Arrhythmias
Applied Therapeutics Dr. Riyadh Mustafa Al-Salih
Arrhythmia Arrhythmia.
ECG Lecture Scott Ewing, D.O. March 23, 2006.
Molecular and Cellular Mechanisms of Cardiac Arrhythmias
Interventional cardiologist & internist
Antiarrhythmic drugs [,æntiə'riðmik] 抗心律失常药
Antiarrhythmic Drugs Types of Cardiac Arrhythmias:
Arrhythmias Simple-dysfunction cause abnormalities in impulse formation and conduction in the myocardium. However, in clinic it present as a complex family.
Implications for safe medication prescribing in older adults
Electrolyte/metabolic disturbance
Presentation transcript:

Introduction The management of wide QRS tachyarrhythmia was documented by advanced cardiac life support (ACLS) guidelines. Delayed or converted the arrhythmia to sinus rhythm unsuccessfully can have fatal consequences with a high mortality rate. In this report, we review five patients suffered from polymorphic ventricular tachycardia (PMVT) or torsade de pointes (TdP) and all the arrhythmias terminated successfully after correcting electrolytes abnormalities. Case Reports There were five patients admitted to our emergency department (ED) due to syncope, dizziness or palpitation. All were found sudden onset of conscious loss with cyanosis during observation at ED and EKG monitor showed TdP or PMVT. Their personal information, past histories, QTc, potassium levels, renal functions, heart functions and treatments were obtained and summarized in the following table. Discussion PMVT is defined as ventricular rhythm faster than 100 beats/minute characterized by clearly defined QRS complexes with frequent and rapid changes in morphology, axis, or both. The clinical presentation can range from a brief, asymptomatic, self- terminate episode to one of recurrent syncope and even degenerate into ventricular fibrillation and may cause death. It is usually associated with long QT syndrome, cardiomyopathy and ischemic heart disease. TdP is a specific type of PMVT. It is universally associated with congenital and acquired long QT syndrome (LQT). The acquired LQT is mostly secondary to drugs and electrolyte disturbances. The drugs most frequently prolonging the QT interval including class Ia and III antiarrhythmic agents (quinidine, procainamide, sotalol, amiodarone), erythromycin, pentamidine, tricyclic antidepressants, lithium, antifungal agents(ketoconazole and itraconazole). The electrolyte disturbances that prolong the QT interval are hypokalemia, hypomagnesaemia and hypocalcemia. Other known associations include subarachnoid hemorrhage, starvation, organophosphoris insecticides, marked bradycardia, myocardial ischemia and cocaine abuse.1 Moreover, female gender is also identified as a risk factor as females have a longer QTc interval than males.2 The potassium ion plays a key role in the normal electrical pulse generation and conduction in the heart. At the cellular level, the repolarisation phase of the myocytes is driven predominantly by outward movement of potassium ions, mainly controlled by Ikr (rapid) and Iks (slow) currents.3 Hypokalemia delays ventricular repolarization and enhanced automaticity which predisposes to TdP. Even mild hypokalemia is a major risk factor for TdP in patients with myocardial ischemia, congestive heart failure, LQT, during anti-arrhythmic therapy or bradyarrhythmias.4 Therefore the target serum potassium concentrations in these patients should be kept 4.5mmol/L or higher. However, in the present of chronic renal failure, serum potassium level should be controlled carefully because mild hyperkalemia can also induced arrhythmias in such patient. PMVT or TdP is a life-threatening arrhythmia that requires immediate treatment. The treatment of choice is immediate cardioversion, starting at 200J and escalating to 300J, then 360J as needed, and usually is successful in terminating the arrhythmia. Once hemodynamic stability has been reestablished, underlying etiology should be evaluated and treated, which includes withdrawal of offending drugs and toxins, correction of underlying electrolyte deficiencies especially hypokalemia, hypomagnesaemia and hypocalcemia. In case of sick sinus syndrome and complete heart block, implantation of a pacemaker.5. Emergency treatment should also includes intravenous magnesium by decreasing the influx calcium ions, which results in decreased amplitude of early after depolarization and suppresses TdP 6, lidocaine, or temporary transvenous overdrive pacing or isoproterenol to prevent immediate recurrences of the arrhythmia by increases heart rate, shortens the QT interval and prevents long pauses 5. Our patients responded promptly after correcting electrolytes abnormalities and no more attack again. We suggested that in patients suffered from refractory tachyarrhythmia especially combined with myocardial ischemia, congestive heart failure, LQT, during anti-arrhythmic therapy, bradyarrhythmias or renal failure, electrolytes abnormalities may be the major risk factors trigger this arrhythmia and should be corrected immediately. Chung-Shun Wong 王忠信, Tzong-Luen Wang 王宗倫, Chiu-Mei Lin 林秋梅 Department of Emergency Medicine, Shin Kong Wu Ho-Su Memorial Hospital COPD: chronic obstructive pulmonary disease, EF: ejection fraction, AR: aortic regurgitation, MR: mitral regurgitation, TR: tricuspid regurgitation, LA: left atrium, LV: left ventricle References 1. Rod Passman and Alan Kadish. Polymorphic Ventricular Tachycardia, Long QT syndrome, and Torsades de pointes. Medical Clinics of North America. 2001;85(2): David Zelter et at. Torsade de pointes due to Noncardiac Drugs. Medicine 2003;82(4): YeeGuan Yap, A John Camm. Drug induced QT prolongation and Torsades de Pointes. Heart 2003;89: Roden DM. Taking the “ idio ” out of “ idiosyncratic ” Predicting torsades de pointes. Pacing Clin Electrophysiol.1998; 21: Khan et al.Torsades de Pointes and Long QT syndrome.Am J Emerg Med 1999;17(1): Tzivoni D, Banai S, Schuger C, et al. Treatment of Torsade de pointes with magnesium sulfate. Circulation 1988;77:392-7 PatientAge/genderQTcKBUN/CrHeart echoPast HistoryTreatments 136 /male /1.1EF:45%,mild global hypokines especially over anterior wall Chronic alcoholismDefibrillation, potassium, magnesium and lidocaine infusion 271/male /1.2EF:51%, moderate TR,AR and trivial MR COPD with cor- pulmonale, and atrial fibrillation Defibrillation, potassium and magnesium infusion. 340/male /1.4EF: 60%, mild MRRenal stone and gouty arthritis Defibrillation, potassium and magnesium infusion 446/male /8.1EF:39%, mild MR, global hypokinesis, dilate LA and LV Diabetes mellitus, hypertension and chronic renal failure Defibrillation, kalimate, sodium biocarbonate and calcium gluconate infusion 539/female /1.0EF:60%-Defibrillation, potassium, lidocaine and amiodarone infusion